Key advances in cardiac computed tomography: A review of the most relevant studies published in 2024 on coronary and structural heart disease
- PMID: 40300917
- DOI: 10.1016/j.jcct.2025.04.008
Key advances in cardiac computed tomography: A review of the most relevant studies published in 2024 on coronary and structural heart disease
Abstract
This review highlights the most relevant and influential studies on coronary and structural cardiac computed tomography published in 2024. The clinical utility of coronary CT angiography (CCTA) continues to expand, supported by advancements in quantitative plaque analysis, functional assessment through FFR-CT, and the integration of artificial intelligence (AI). Photon-counting CT has emerged as a promising technology for improving image quality and diagnostic accuracy. In structural heart disease, CCT has become an indispensable tool for procedural planning and risk stratification across multiple valvular interventions. Moreover, CT-derived extracellular volume (CT-ECV) and AI-based assessment of myocardial mass and epicardial adipose tissue are gaining traction as novel prognostic biomarkers. These developments reflect the growing adoption of CCT in both clinical practice and cardiovascular research, underscoring its role as a cornerstone modality in modern cardiology.
Keywords: Artificial intelligence; Cardiac computed tomography; Coronary artery disease; Quantitative plaque analysis; Structural heart disease.
Copyright © 2025 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Hector M. Garcia-Garcia is a consultant for Boston Scientific, Abbott, Medis. His institution receives research grants from: Boston Scientific, Abbott, Chiesi, Biotronik, Cordis, Medis, Phillips. Carlo DeCecco reports Research grant/consultant Siemens, Cleerly, Elucid. Cristina Fuss is a consultant for HeartFlow. Maros Ferencik reports consulting fees from Cleerly, HeartFlow, Elucid, and BioMarin, advisory board of Cleerly and Elucid, and stock options Elucid. Jonathan A. Leipsic is a consultant for Circle CVI and Heartflow. Prashant Nagpal reports consulting fees from GE Healthcare, WCG Clinical and grant support from Canon Medical and stock ownership of Moderna. Ming-Yen Ng has received speaker fees from Circle CVI, GE Healthcare, Boerhinger Ingelheim, Bayer and grant support from Bayer, GE Healthcare, TeraRecon. Florian Michallek’s institution receives endowment support from Siemens Japan. Edward Nicol is a member of Caristo Diagnostics Scientific Advisor Board. Benjamin Chow receives research support from TD Bank and Artrya. He is a consultant for Artrya and has an equity interest in: Artrya, Becton Dickson and Co, McKesson, Proctor and Gamble. Armin Arbab-Zadeh receives research support from Canon Medical Systems and Royalties from Nature-Springer. All other authors have no relevant disclosures.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical